Modality
Fusion Protein
MOA
BCL-2i
Target
USP1
Pathway
DDR
LGS
Development Pipeline
Preclinical
Sep 2021
→ Sep 2027
PreclinicalCurrent
NCT03742838
1,951 pts·LGS
2021-09→TBD·Recruiting
NCT06675378
2,830 pts·LGS
2022-11→2027-09·Terminated
4,781 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-281.5y awayInterim· LGS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Interim
2027-09-28 · 1.5y away
LGS
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03742838 | Preclinical | LGS | Recruiting | 1951 | UPCR |
| NCT06675378 | Preclinical | LGS | Terminated | 2830 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 |